23 LC 33 9402

Senate Bill 223

By: Senators Watson of the 1st, Tillery of the 19th, Brass of the 28th, Hufstetler of the 52nd, Robertson of the 29th and others

AS PASSED

A BILL TO BE ENTITLED AN ACT

- 1 To amend Chapter 1 of Title 31 of the Official Code of Georgia Annotated, relating to
- 2 general provisions regarding health, so as to authorize reimbursement of patient incurred
- 3 expenses related to participation in a cancer clinical trial; to provide for definitions; to require
- 4 certain information to be provided to potential participants during the informed consent
- 5 process; to provide that reimbursement shall not be considered undue inducement; to provide
- 6 for review of information provided to potential participants to be reviewed by the relevant
- 7 federally designated institutional review board; to require disclosure of ancillary support; to
- 8 provide for related matters; to repeal conflicting laws; and for other purposes.

9 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

SECTION 1.

- 11 Chapter 1 of Title 31 of the Official Code of Georgia Annotated, relating to general
- 12 provisions regarding health, is amended by adding a new Code section to read as follows:
- 13 "31-1-25.
- 14 (a) As used in this Code section, the term:
- 15 (1) 'Cancer clinical trial' means a research study that tests a new cancer treatment
- regimen on patients, including chemotherapy and other new treatments.

23 LC 33 9402

17 (2) 'Inducement' means paying a person money, including a lump sum or salary payment,

- 18 <u>to participate in a cancer clinical trial.</u>
- 19 (3) 'Patient-subject' means a person participating in a cancer clinical trial.
- 20 (b) All sponsors of cancer clinical trials shall provide potential patient-subjects at the time
- 21 of the informed consent process the following information:
- 22 (1) Whether reimbursement for travel and ancillary costs may be available to
- 23 <u>patient-subjects</u>;
- 24 (2) That coverage of the travel and ancillary costs is provided to eliminate financial
- barriers to enrollment in order to retain patient-subjects in the cancer clinical trial; and
- 26 (3) Whether family members, friends, or chaperones who attend the cancer clinical trial
- 27 <u>treatments to support the patient-subject may be eligible for reimbursement of their travel</u>
- and ancillary costs.
- 29 (c)(1) Reimbursement of travel, ancillary costs, and other direct patient incurred
- 30 <u>expenses related to cancer clinical trial participation shall not be considered an undue</u>
- 31 <u>inducement for participation in a cancer clinical trial.</u>
- 32 (2) Reimbursement for travel and ancillary costs shall not be considered coercive or as
- 33 <u>exerting undue influence for participation in a cancer clinical trial, but rather, shall be</u>
- 34 considered a means to create parity in cancer clinical trial access and remove a barrier to
- 35 participation for financially burdened patient-subjects.
- 36 (3) Government, industry, public charities, private foundations and other nonprofit
- 37 <u>organizations, associations, corporations and other business entities, individuals, and any</u>
- 38 other legal or commercial entities may offer financial support to patient-subjects, or the
- 39 <u>family members, friends, or chaperones of patient-subjects, to cover ancillary costs</u>
- 40 <u>through their support of a reimbursement entity or program.</u>
- 41 (d)(1) Language informing patient-subjects that reimbursement entities or programs that
- 42 <u>cover travel, ancillary costs, and other direct patient incurred expenses may be available</u>
- 43 <u>shall be submitted for review to the relevant federally designated institutional review</u>

23 LC 33 9402

board in conjunction with the review of a proposed cancer clinical trial and included in
 the informed consent form approved by the institutional review board.

- 46 (2) A reimbursement entity or program shall disclose the nature of the ancillary support
- 47 <u>and general guidelines on financial eligibility to interested patient-subjects and shall</u>
- 48 employ a reimbursement process that conforms to federal law and guidance."

49 **SECTION 2.**

50 All laws and parts of laws in conflict with this Act are repealed.